ADAG Adagene ADS (N Shares)

Adagene to Present at the Leerink Partners Global Biopharma Conference 2024

Adagene to Present at the Leerink Partners Global Biopharma Conference 2024

SAN DIEGO and SUZHOU, China, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in the Leerink Partners Global Biopharma Conference 2024, taking place March 11-13 in Miami, Florida.

Adagene’s Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will provide an update on its masked, anti-CTLA-4 SAFEbody® ADG126, including key milestones for 2024. Company management will also host investor meetings.

Leerink Partners Global Biopharma Conference 2024

  • Date:     
Tuesday, March 12
  • Presentation Time:
1:40 PM (Eastern Time)
  • Location:
The Fontainebleau Miami

A live webcast of the presentation will also be accessible in the section of the company’s website at . A webcast replay will be available for at least 30 days.

About Adagene

Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody®, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.

For more information, please visit: . Follow Adagene on ,  and .

SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.

Investor & Media Contact:

Ami Knoefler

Adagene

650-739-9952



EN
27/02/2024

Underlying

ADAGAdagene ADS (N Shares)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Adagene ADS (N Shares)

 PRESS RELEASE
Free
ADAG Adagene ADS (N ...

Adagene Presents Two Posters with New Insights on Increased Therapeuti...

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - Improved safety and efficacy profiles for ADG126 versus ipilimumab driven by precision masking, novel epitope-dependent antibody-dependent cellular cytotoxicity (ADCC) and partial CTLA-4 blockade - - Clinical data show benefit of combining immune checkpoint inhibitors in MSS C...

November 7, 2024 1 EN
 PRESS RELEASE
Free
ADAG Adagene ADS (N ...

Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 ...

Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting SAN DIEGO and SUZHOU, China, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced poster presentations at the upcoming SITC 39th Annual Meeting, taking place in Houston, Nov. 6 – 10, 2024. Details include: Deciphering Improved Clinical Therapeutic Index (TI) of Muzastotug (ADG126), a Masked Anti-CTLA...

October 9, 2024 1 EN
 PRESS RELEASE
Free
ADAG Adagene ADS (N ...

Adagene Presents Results at ESMO Congress that Show Best-in-Class Ther...

Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) - Confirmed partial responses (PRs) doubled to four since ASCO GI in MSS CRC patients without liver and peritoneal metastases for overall response rate (ORR) of 24% (4/17) with ADG126 10 mg/kg every three weeks (Q3W) in combination with pembrolizumab - - Median progression-free survival of 8.5 months observed in patients without liv...

September 16, 2024 1 EN
 PRESS RELEASE
Free
ADAG Adagene ADS (N ...

Adagene to Participate in Investor Conferences in September

Adagene to Participate in Investor Conferences in September SAN DIEGO and SUZHOU, China, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the company’s participation in several upcoming investor conferences in New York City. Management will host investor meetings and Adagene’s Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will present at the following events: Morgan Stanley 22nd Annual G...

August 29, 2024 1 EN
 PRESS RELEASE
Free
ADAG Adagene ADS (N ...

Adagene Reports Six Month Financial Results for 2024 and Provides Corp...

Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update - Potential best-in-class therapeutic index for lead candidate anti-CTLA-4 SAFEbody® ADG126 (muzastotug) with higher, more frequent and repeat dosing in combination with Merck’s anti-PD-1 therapy KEYTRUDA* (pembrolizumab) to unleash potential efficacy, while maintaining safety comparable to pembrolizumab alone -  - Poster planned at European Society of Medical Oncology (ESMO) Congress 2024 in September for ADG126 in combination with pembrolizumab in metastatic microsatellite-stable (MSS) colorectal cancer (C...

July 25, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch